Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors

Intracranial germ cell tumors (GCT) account for less than 5% of all central nervous system tumors in children in Western countries. Approximately 40% are nongerminomatous GCT (NGGCT). Despite correct treatment, 16% to 47% of the patients will relapse. There are no standard approaches in case of recurrence, and treatment in this situation remains a challenge.

[1]  J. Finlay,et al.  Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors , 2018, Child's Nervous System.

[2]  G. Horan,et al.  Current Management of Intracranial Germ Cell Tumours. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

[3]  Kaleigh Fetcko,et al.  Primary Central Nervous System Germ Cell Tumors: A Review and Update. , 2018, Medical research archives.

[4]  J. Mann,et al.  Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial , 2017, Neuro-oncology.

[5]  J. Mann,et al.  Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first‐line therapy , 2017, International journal of cancer.

[6]  C. Bokemeyer,et al.  Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group. , 2016, Urologic oncology.

[7]  S. All,et al.  Re-irradiation of Recurrent Pineal Germ Cell Tumors with Radiosurgery: Report of Two Cases and Review of Literature , 2016, Cureus.

[8]  T. Zhou,et al.  Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Soo Hyun Lee,et al.  Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study , 2013, Journal of Neuro-Oncology.

[10]  S. Malone,et al.  Successful salvage using combined radiation and ABMT for patients with recurrent CNS NGGCT following failed initial transplant , 2012, BMJ Case Reports.

[11]  C. Bokemeyer,et al.  Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. , 2011, European urology.

[12]  R. Coleman,et al.  Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours. , 2005, Cancer treatment reviews.

[13]  M. Marangolo,et al.  Weekly Gemcitabine, Paclitaxel, Oxaliplatin Combination Chemotherapy in Patients With Cisplatin-Refractory Germ Cell Tumor: Preliminary Experience , 2004, American journal of clinical oncology.

[14]  N. Foreman,et al.  Intracranial Germ Cell Tumors: A Single Institution Experience and Review of the Literature , 2004, Journal of Neuro-Oncology.

[15]  Douglas C. Miller,et al.  Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Onishi,et al.  Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors , 2003, Cancer.

[17]  C. Bokemeyer,et al.  Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.